Dealmaking Quarterly Statistics, Q3 2020
A Look At M&A And Alliance Activity Across The Biopharma, Medical Device And In Vitro Diagnostics Industries, July-September 2020
During Q3 biopharmas reached $41.7bn in merger and acquisition value and drew in $44.4bn in potential deal value from alliances. Device company M&A values reached $17.9bn while in vitro diagnostic firms and research tools players completed M&A activity that totaled $8.2bn.
You may also be interested in...
Avenu’s Ellipsys vascular access system is an ultrasound-guided catheter to create a durable arteriovenous fistula for patients undergoing dialysis.
Integra is divesting its underperforming extremity orthopedics product portfolio to focus on its neurosurgery, surgical instrument and regenerative medicine businesses.
Illumina announced today it will buy back Grail to allow faster adoption of its liquid biopsy test.